期刊文献+

双水平正压无创机械通气治疗重症支气管哮喘的探讨 被引量:22

Observation of clinical efficacy of BiPAP non-invasive mechanical ventilation treatment on patients with severe asthma
下载PDF
导出
摘要 目的探讨双水平正压无创机械通气治疗重症支气管哮喘的临床效果。方法60例重症支气管哮喘患者随机分为观察组和对照组各30例,对照组采用传统治疗方法,观察组采用无创机械通气模式和基础治疗。比较两组实施治疗前、治疗3d后患者临床症状、体征变化及动脉血气指标(PaCO2、PaO2、SaO2)变化。结果两组患者比较差异有统计学意义,P<0.01。结论在常规治疗的基础加用无创通气治疗,可有效改善患者的临床症状,安全有效,减少患者痛苦。 Objective To evaluate the clinical efficacy of BiPAP non-invasive mechanical ventilation in the treatment of patients with severe asthma. Methods 60 patients with severe asthma were divided into the intervention group(30 cases) and control group(30 cases). The control group were given routine treatment,the intervention group were treated with BiPAP ventilation in addition to the routine treatment. The measures of changes of clinical symptoms and arterial blood gas( PaCO2, PaO2 and SaO2 ) before and 3 days after the treatment were compared. Results There was obvious difference between the two groups:P 〈 0. 01. Conclusion Using non-invasive ventilation based on routine treatment can improved the clinical manifestation,which is efficient,safe and less painful.
出处 《临床肺科杂志》 2009年第10期1335-1336,共2页 Journal of Clinical Pulmonary Medicine
关键词 双水平正压通气 无创机械通气 重症支气管哮喘 疗效 BiPAP non-invasive mechanical ventilation severe asthma effect
  • 相关文献

参考文献6

二级参考文献22

  • 1贺正一,刘绍珊,张希玲,赵岩.慢阻肺呼吸衰竭纤支镜引导经鼻插管与气管切开的比较[J].中国实用内科杂志,1995,15(4):216-217. 被引量:35
  • 2Schenlag J J,Ballow C H. Tissue-directed pharmacokinetice. Am J Mel,1991 ,91(3A):5.
  • 3Torphy TJ. Phosphodiestease isozymes; Molecular targets for novel anti-asthma agents. Am J Respir Crit Care Med 1998;157:35170.
  • 4Torphy TJ, Barnette MS, Underwood DC, et al. Ariflo (SB 207499), a second generation Phosphodiestease 4 inhibitor for the treatment of asthma and COPD: from concept to clinic. Pulm Pharmacol Ther 1999 - 12 : 131 - 35.
  • 5Manning CD, Burman M, Christensen SB, et al. Suppresion of human inflamma-tory cell functionby subtype selective PDE-4 inhibitors correlates with inhibition of PDE4A and PDE4B. Br J Clin Pharmcol ; 128:1393 -98.
  • 6Hatzelmann A,Schudt C. Anti-inflammatory and imnmnomodulatory potential of the novel PDE-4 inhibitor roflumilast in vitro. J Pharmacol Exp Ther 2001, 297 : 267- 79.
  • 7Wollin N, Bundschuh DS, Ostermann A, et al. Inhibition of asthma key medlar-ors and inflammation by roflumilast:effects on the time course in ovalbumin challenged brown Norway rats.Am J Respir Crit Care Med 2004; 169:A803(abstr).
  • 8Boswell-Smith V, Spina D, Page CP. Regulation by selective Phosphodieste-ase 4 isoenzyme inhibitor of non-adrenergic,non cholinergic contract on guinea pig isolated main bronchus. Am J Respir Crit Care Med 2004; 169:A180(abstr).
  • 9Zussman BD,Benincosa LJ,Webber DM0e(al. An overview of the pharmaco-kinetics of cilomilast (Ariflo), a new , Orally active Phosphodiestease 4 inhibitor, in healthy young and elderly volunteers. J Clin Pharmacol 2001 , 41 : 950- 98.
  • 10Mangegold A, Hauns B, David M, Zech K, Wurst W.Pharmacokinetic character-istics of roflumilast administered in gradually increasing doses of 500mcg to 1000mcg are dose linear in healthy subjects. Eur Respir J 2002; 20(suppl 38);108S(abstr).

共引文献3633

同被引文献123

引证文献22

二级引证文献132

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部